WO2021152623A1 - Procédés améliorés pour la préparation de tafamidis et de son sel de méglumine - Google Patents

Procédés améliorés pour la préparation de tafamidis et de son sel de méglumine Download PDF

Info

Publication number
WO2021152623A1
WO2021152623A1 PCT/IN2021/050078 IN2021050078W WO2021152623A1 WO 2021152623 A1 WO2021152623 A1 WO 2021152623A1 IN 2021050078 W IN2021050078 W IN 2021050078W WO 2021152623 A1 WO2021152623 A1 WO 2021152623A1
Authority
WO
WIPO (PCT)
Prior art keywords
tafamidis
salt
methyl
meglumine
acid
Prior art date
Application number
PCT/IN2021/050078
Other languages
English (en)
Inventor
Srinivas ORUGANTI
Vishnu Vardhana Vema Reddy EDA
Balachennaiah DARAPANENI
Rajeev Rehani BUDHDEV
Mohammed Azeezulla Baig
Saikat Sen
Kottur Mohan Kumar
Shaunak Chakraborty
Nekkanti Satish Chowdary
Satyanarayana THIRUNAHARI
Original Assignee
Dr. Reddy’S Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Reddy’S Laboratories Limited filed Critical Dr. Reddy’S Laboratories Limited
Publication of WO2021152623A1 publication Critical patent/WO2021152623A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/12—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic the nitrogen atom of the amino group being further bound to hydrocarbon groups substituted by hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • the present invention relates to improved processes for the preparation of Tafamidis and a salt thereof.
  • the present invention also relates to one-pot process for the preparation of Tafamidis and its purification.
  • the present invention relates to amorphous solid dispersions of Tafamidis and its meglumine salt, and their processes.
  • the present invention also relates to novel crystalline forms of Tafamidis and their processes.
  • the drug compound having the adopted name “Tafamidis” has chemical name: 2-(3,5-dichlorophenyl)-l,3-benzoxazole-6-carboxylic acid as below.
  • Tafamidis is a selective stabilizer of transthyretin developed by The Scripps Research Institute and marketed by Pfizer as VYNDAQEL® (Tafamidis meglumine) and VYNDAMAXTM (Tafamidis) oral capsule for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular - related hospitalization in U.S.
  • US7214695B2 disclosed Tafamidis and its use thereof for the treatment of transthyretin amyloid disease. US7214695B2 further discloses a general procedure for the preparation of benzoxazoles, particularly Tafamidis (compound 19) with 11% yield.
  • the US9249112B2 patent discloses the preparation of meglumine salt of Tafamidis from the mixture of isopropyl alcohol and water. It further discloses the crystalline and amorphous forms of Tafamidis meglumine.
  • the US9770441B1 discloses amorphous and crystalline forms 1, 2, 4 and 6 of Tafamidis.
  • the patent further patent discloses alternate procedure for the preparation of Tafamidis with enhanced yield, however the process disclosed therein involves multiple downstream operations such as isolation, solvent displacement through distillation for the purification of intermediates and Tafamidis, though the patent is silent about the resultant purity and other quality attributes.
  • the present invention provides a one-pot process for the preparation of Tafamidis or a salt thereof, comprising the steps of:
  • step (ii) cyclization of the amide intermediate formed in step (i), wherein the amide intermediate is not isolated;
  • step (iii) optionally, converting Tafamidis obtained at step (ii) in to a salt thereof.
  • the present invention a provides process for the preparation of Tafamidis or its meglumine salt, comprising step of preparing Tafamidis organic base addition salt.
  • the present invention provides the organic base addition salt form of Tafamidis selected from the group consisting of benzylamine, dicyclohexylamine and diethanolamine salts of Tafamidis.
  • the present invention provides use of organic base addition salt of Tafamidis, for the manufacture of Tafamidis or its meglumine salt.
  • the present invention provides use of organic base addition salt form of Tafamidis selected from the group consisting of benzylamine, dicyclohexylamine and diethanolamine salts of Tafamidis, for the manufacture of Tafamidis or its meglumine salt.
  • the present invention provides an amorphous solid dispersion of Tafamidis or its meglumine salt, together with atleast one pharmaceutically acceptable excipient.
  • the present invention provides a process for the preparation of amorphous solid dispersion of Tafamidis or its meglumine, comprising the steps of: a) combining Tafamidis or its meglumine salt with atleast one pharmaceutically acceptable excipient in a suitable solvent or mixtures thereof, b) Removing the solvent from step a).
  • the present invention provides a crystalline Form-Tl of Tafamidis, characterized by a PXRD pattern comprising the peaks at about 5.90, 20.53 and 29.24° ⁇ 0.2° 2Q.
  • the present invention provides a crystalline Form-T2 of Tafamidis, characterized by a PXRD pattern comprising the peaks at about 12.93, 15.07 and 19.57° ⁇ 0.2° 2Q.
  • the present invention provides a crystalline Form-T3 of Tafamidis, characterized by a PXRD pattern comprising the peaks at about 14.43, 21.59 and 22.95 ° ⁇ 0.2° 2Q.
  • the present invention provides a crystalline Form-T4 of Tafamidis, characterized by a PXRD pattern comprising the peaks at about 8.17, 21.09, 24.75° ⁇ 0.2° 2Q.
  • the present invention provides a process for the preparation of crystalline Form-Tl of Tafamidis, comprising the step of combining Tafamidis with 2-methoxyethanol.
  • the present invention provides a process for the preparation of crystalline Form-T2 of Tafamidis, comprising the step of combining Tafamidis with N-methyl-2-pyrrolidone.
  • the present invention provides a process for the preparation of crystalline Form-T3 of Tafamidis, comprising the step of combining Tafamidis with dimethyl acetamide.
  • the present invention provides a process for the preparation of crystalline Form-T4 of Tafamidis, comprising the step of combining Tafamidis with dimethyl sulfoxide.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising crystalline Tafamidis, selected from the group consisting of Form-Tl, Form-T2, Form-T3, Form-T4 and mixtures thereof, and atleast one pharmaceutically acceptable excipient.
  • Figure 1 is an illustrative X-ray powder diffraction pattern of crystalline Tafamidis meglumine salt prepared by the methods of Example No 3.
  • Figures 2, 4, 6, 8 and 10 are the illustrative X-ray powder diffraction pattern of crystalline Tafamidis prepared by the methods of Example No 4, 6, 7, 8 and 9, respectively.
  • Figure 3 is an illustrative X-ray powder diffraction pattern of crystalline Tafamidis benzylamine salt prepared by the methods of Example No 6.
  • Figure 5 is an illustrative X-ray powder diffraction pattern of crystalline Tafamidis benzylamine salt prepared by the methods of Example No 7.
  • Figure 7 is an illustrative X-ray powder diffraction pattern of crystalline Tafamidis dicyclohexylamine salt prepared by the methods of Example No 8.
  • Figure 9 is an illustrative X-ray powder diffraction pattern of crystalline Tafamidis dicyclohexylamine salt prepared by the methods of Example No 9.
  • Figure 11 is illustrative Thermogravimetric/Differential Thermal
  • FIG 12 is illustrative Thermogravimetric/Differential Thermal Analyzer (TG/DTA) pattern of crystalline Tafamidis benzylamine salt prepared by the methods of Example No 7.
  • TG/DTA Thermogravimetric/Differential Thermal Analyzer
  • FIG 13 is illustrative Thermogravimetric/Differential Thermal Analyzer (TG/DTA) pattern of crystalline Tafamidis dicyclohexylamine salt prepared by the methods of Example No 8.
  • TG/DTA Thermogravimetric/Differential Thermal Analyzer
  • FIG 14 is illustrative Thermogravimetric/Differential Thermal Analyzer (TG/DTA) pattern of crystalline Tafamidis dicyclohexylamine salt prepared by the methods of Example No 9.
  • TG/DTA Thermogravimetric/Differential Thermal Analyzer
  • Figure 15 is illustrative X-ray powder diffraction pattern of crystalline Tafamidis diethanolamine salt prepared by the methods of Example No 10.
  • FIG 16 is illustrative Thermogravimetric/Differential Thermal Analyzer (TG/DTA) pattern of crystalline Tafamidis diethanolamine salt prepared by the methods of Example No 10.
  • TG/DTA Thermogravimetric/Differential Thermal Analyzer
  • Figures 17 to 20 are the illustrative X-ray powder diffraction patterns of amorphous solid dispersions of Tafamidis prepared by the methods of Example 11 to 14.
  • Figure 21 is an illustrative X-ray powder diffraction pattern of amorphous form of Tafamidis meglumine prepared by the methods of Example 15.
  • Figure 22 is an illustrative X-ray powder diffraction patterns of amorphous solid dispersions of Tafamidis meglumine salt prepared by the methods of Example 16.
  • Figure 23 is an illustrative X-ray powder diffraction pattern of crystalline Form-Tl of Tafamidis, prepared by the method of Example No 20.
  • Figure 24 is an illustrative X-ray powder diffraction pattern of crystalline Form-T2 of Tafamidis, prepared by the method of Example No 21.
  • Figure 25 is an illustrative X-ray powder diffraction pattern of crystalline Form-T3 of Tafamidis, prepared by the method of Example No 22.
  • Figure 26 is an illustrative X-ray powder diffraction pattern of crystalline Form-T4 of Tafamidis, prepared by the method of Example No 23. DETAILED DESCRIPTION OF THE INVENTION
  • the present invention provides a one-pot process for the preparation of Tafamidis or a salt thereof, comprising the steps of:
  • step (ii) cyclization of amide intermediate formed in step (i), wherein the amide intermediate is not isolated;
  • the starting materials used in this aspect may be obtained according to any method known in the art or may be procured from the commercially available sources.
  • step (i) of this aspect may be carried out in the presence of suitable organic solvent.
  • step (i) of this aspect may be carried out in the presence of organic solvent consisting of N-methyl 2- pyrrolidone in toluene.
  • organic solvent consisting of N-methyl 2- pyrrolidone in toluene.
  • step (i) may be carried at a suitable temperature of about 0 °C to reflux temperature of the solvent used.
  • step (i) may be carried out for sufficient time for the formation of amide intermediate and till the content of starting materials are not detected in the reaction mixture. In embodiments, step (i) may be carried out for at least one hour or more.
  • step (ii) of this aspect may be carried out without isolation of amide intermediate formed at step (i).
  • the step (ii) of this aspect may be carried out in the presence of a suitable cyclization promoter.
  • the cyclization promoter that can used in this step may include but not limited to sulfonic acids such as p- toluenesulfonic acid, benzenesulfonic acid, p-nitrobenzenesulfonic acid, trifluoromethanesulfonic acid and methanesulfonic acid; mineral acids such as sulfuric acid and hydrochloric acid; organic acids and their anhydrides such as acetic acid and acetic anhydride; acidic resins; boric acid; phosphorous pentoxide; polyphosphoric acid (PPA); phosphoryl chloride; molecular sieves or mixtures thereof.
  • p-toluenesulfonic acid as cyclization promoter is employed.
  • step (ii) may be carried at a suitable temperature of about 0 °C to reflux temperature of the solvent used. In preferred embodiments, step (ii) may be carried out at reflux temperature of the solvent used.
  • step (ii) may be carried out for sufficient time for the complete cyclization of amide intermediate and till the content of amide intermediate is not detected in the reaction mixture. In embodiments, step (i) may be carried out for at least one hour or more.
  • Tafamidis obtained at step (ii) may be converted to a salt form.
  • the present invention provides a process for the preparation of Tafamidis or its meglumine salt, comprising step of preparing Tafamidis organic base addition salt.
  • the organic base for the organic base addition salt of Tafamidis may be selected from the group consisting of meglumine, dicyclohexylamine, benzylamine, dibenzylamine, phenylethylamine, 1-(1- naphthyl)ethylamine, tert-butylamine, N-methyl pyrrolidone, 1,4- diazabicyclo[2.2.2]octane, triethylamine, diisopropylethylamine, 1- methylpyrrolidine, tromethamine, pyridine, l,8-diazabicyclo[5.4.0]undec-7- ene, hexylamine, 2,6-lutidine, piperidine, diethylamine, dibutylamine, morpholine, 3 -dimethylamino-1 -propylamine, diisopropylamine, N-benzyl-tert- butylamine, diethanolamine, l,
  • the step of generating Tafamidis from its organic base addition salt form may be carried out by treating the salt with an acid.
  • Suitable acid may include, but not limited to mineral acids such as hydrochloric acid, sulfuric acid, hydrobromic acid, phosphoric acid, perchloric acid; carboxylic acids such as formic acid, trifluoroacetic acid, trichloroacetic acid, oxalic acid, fumaric acid and maleic acid; and sulfonic acids such as p-toluenesulfonic acid (PTSA), benzenesulfonic acid, p-nitrobenzenesulfonic acid, trifluoromethanesulfonic acid and methanesulfonic acid.
  • PTSA p-toluenesulfonic acid
  • treating organic base addition salt with an acid may be carried out in the presence of a suitable solvent.
  • Inventors of the present invention have identified that the process of preparation of Tafamidis through the treatment of organic base addition salt form of Tafamidis surprisingly improves the chemical purity significantly as illustrated below.
  • Inventors of the present invention have identified that treatment of Tafamidis free form with inorganic bases does not result in solid form of Tafamidis inorganic base addition salts & thus may not be useful for purification of Tafamidis to achieve desired chemical purity. More particularly, it was observed that preparation of Tafamidis through the treatment of inorganic base addition salt leads to a chemical purity of not more than about 98.5% by HPLC, which is not acceptable as per the regulatory requirements.
  • the present invention provides salt form of Tafamidis selected from the group consisting of benzylamine, dicyclohexylamine and diethanolamine salts of Tafamidis.
  • the salt form is benzylamine salt of Tafamidis.
  • the benzylamine salt of Tafamidis is amorphous salt.
  • the benzylamine salt of Tafamidis is crystalline salt.
  • the crystalline benzylamine salt of Tafamidis is characterized by the PXRD pattern of figures 3 or 5.
  • the crystalline benzylamine salt of Tafamidis is characterized by Thermogravimetric/Differential Thermal Analyzer (TG/DTA) pattern of figure 11 or 12.
  • the salt form is dicyclohexylamine salt of Tafamidis.
  • the dicyclohexylamine salt of Tafamidis is amorphous salt.
  • the dicyclohexylamine salt of Tafamidis is crystalline salt.
  • the crystalline dicyclohexylamine salt of Tafamidis is characterized by the PXRD pattern of figures 7 or 9.
  • the crystalline dicyclohexylamine salt of Tafamidis is characterized by Thermogravimetric/Differential Thermal Analyzer (TG/DTA) pattern of figure 13 or 14.
  • the salt form is diethanolamine salt of Tafamidis.
  • the diethanolamine salt of Tafamidis is amorphous salt.
  • the diethanolamine salt of Tafamidis is crystalline salt.
  • the crystalline diethanolamine salt of Tafamidis is characterized by the PXRD pattern of figures 15.
  • the crystalline diethanolamine salt of Tafamidis is characterized by Thermogravimetric/Differential Thermal Analyzer (TG/DTA) pattern of figure 16.
  • the present invention provides a process for the preparation of organic base addition salt form of Tafamidis, comprising steps of: i) treating Tafamidis with organic base in one or more of suitable solvents and ii) isolating organic base addition salt form of Tafamidis.
  • the base used in step i) may be selected from the group captured in above embodiments.
  • meglumine, dicyclohexylamine, benzylamine, diethanolamine or dibenzylamine are the bases.
  • the present invention provides Tafamidis or its meglumine salt, obtained according to the processes of the present invention, having a chemical purity of at least 99% or at least 99.5 or at least 99.9%, by HPLC.
  • the present invention provides use of organic base addition salt form of Tafamidis selected from the group consisting of benzylamine, dicyclohexylamine and diethanolamine salts of Tafamidis, for the manufacture of Tafamidis or its meglumine salt.
  • the present invention provides use of diethanolamine salt of Tafamidis, for the manufacture of Tafamidis or its meglumine salt.
  • the present invention provides use of organic base addition salts for the manufacture of Tafamidis or its meglumine salt increases the chemical purity to more than 98.5% by HPLC.
  • the present invention provides a process for the preparation of substantially pure Tafamidis or its meglumine salt, comprising step of preparing Tafamidis organic base addition salt.
  • pure When a molecule or other material is identified herein as “pure”, it generally means, unless specified otherwise, that the material is 98.5% pure or more, as determined by methods conventional in art such as high performance liquid chromatography (HPLC) or optical methods.
  • HPLC high performance liquid chromatography
  • substantially pure refers to the same as “pure” except that the lower limit is about 98.5% pure or more and likewise.
  • the present invention provides Tafamidis or its meglumine salt, obtained according the processes of above aspects.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising Tafamidis or its meglumine salt, obtained according the processes of above aspects and at least one pharmaceutically acceptable excipient.
  • the present invention provides amorphous solid dispersion of Tafamidis or its meglumine salt, together with atleast one pharmaceutically acceptable excipient, as characterized by a powder X-ray diffraction (PXRD) pattern, substantially as illustrated by Figures 17 to 20 or 22.
  • PXRD powder X-ray diffraction
  • At least one pharmaceutically acceptable excipient of this aspect may be selected from the group consisting of polyvinyl pyrrolidone, povidone K-30, povidone K-60, Povidone K-90, polyvinylpyrrolidone vinylacetate, co-povidone NF, polyvinylacetal diethylaminoacetate (AEA®), polyvinyl acetate phthalate, polysorbate 80, polyoxyethylene-polyoxypropylene copolymers (Poloxamer® 188), polyoxyethylene (40) stearate, polyethyene glycol monomethyl ether, polyethyene glycol, poloxamer 188, pluronic F-68, methylcellulose, methacrylic acid copolymer (Eudragit or Eudragit-RLPO), hydroxypropylmethyl cellulose (HPMC), hydroxypropyl cellulose (HPC), hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succ
  • Solid dispersions of the present application also include the solid dispersions obtained by combining Tafamidis or its meglumine salt with a suitable non-polymeric excipient by employing techniques known in the art or procedures described or exemplified in any aspect of the instant invention.
  • the present invention provides a process for the preparation of amorphous solid dispersion of Tafamidis or its meglumine, comprising the steps of: a) combining Tafamidis or its meglumine salt with atleast one pharmaceutically acceptable excipient in a suitable solvent or mixtures thereof, b) Removing the solvent from step a).
  • Tafamidis or its meglumine salt may be combined with atleast one pharmaceutically acceptable excipient, under heating or mechanical stress to obtain molten mixture of components.
  • the molten mixture may be optionally cooled to obtain solid dispersion of Tafamidis or its meglumine salt with atleast one pharmaceutically acceptable excipient.
  • Tafamidis or its meglumine salt may be combined with atleast one pharmaceutically acceptable excipient in a suitable equipment such as hot melt extruder, twin screw extruder or the like.
  • Tafamidis or its meglumine salt may be combined with pharmaceutically acceptable excipient in the presence of a suitable solvent.
  • the suitable solvent can be selected from the list of solvents disclosed in the application herein.
  • At least one pharmaceutically acceptable excipient of this aspect may be selected from the group of excipients of the previous aspect.
  • combining Tafamidis or its meglumine salt may be carried out by dissolving Tafamidis or its meglumine salt and at least one pharmaceutically acceptable excipient simultaneously or separately in same or different solvents.
  • a solution of Tafamidis or its meglumine salt and the excipient may be prepared at any suitable temperature, such as about 0 °C to about the reflux temperature of the solvent used. Stirring and heating may be used to reduce the time required for the dissolution process.
  • a solution of Tafamidis or its meglumine salt and the excipient may be filtered to make it clear and free of unwanted particles.
  • the obtained solution may be optionally treated with an adsorbent material, such as carbon and/or hydrose, to remove colored components, etc., before filtration.
  • the solvent from the solution of Tafamidis or its meglumine salt and the excipient may be removed as per the methods described in this application.
  • the solid obtained can be dried as per the methods disclosed in this application.
  • the isolation of the solid dispersion of Tafamidis or its meglumine salt with excipient is performed as per the methods described in this application.
  • the solid dispersions of Tafamidis or its meglumine salt of the present application are stable under thermal, humid and stress conditions. Further, the solid dispersions of Tafamidis or its meglumine salt of present application exhibits superior solubility in solvents such as water, as compared to reported crystalline forms of Tafamidis or its meglumine salt.
  • the present application provides a solid dispersion of Tafamidis or its meglumine salt, obtained according to the processes of the present application, having a chemical purity of atleast 99% or atleast 99.5% by HPLC.
  • the present invention relates to solid forms of Tafamidis and the pharmaceutical compositions thereof. Specific aspect of present application relate to crystalline Form-Tl, Form-T2, Form-T3 and Form-T4 of Tafamidis and their preparative processes.
  • the present invention provides a crystalline Form-Tl of Tafamidis, characterized by a PXRD pattern comprising the peaks at about 5.90, 20.53 and 29.24° ⁇ 0.2° 2Q.
  • the crystalline Form-Tl is characterized by one or more additional peaks at about 9.72, 17.62, 19.91 and 24.06° ⁇ 0.2° 2Q.
  • the present invention provides crystalline Form-Tl of Tafamidis, characterized by a powder X-ray diffraction pattern, as illustrated by Figure 23.
  • the present invention provides a crystalline Form-T2 of Tafamidis, characterized by a PXRD pattern comprising the peaks at about 12.93, 15.07 and 19.57° ⁇ 0.2° 2Q.
  • the crystalline Form-T2 is characterized by one or more additional peaks at about 10.01, 24.40, 27.72 and 28.31° ⁇ 0.2° 2Q.
  • the present application provides crystalline Form-T2 of Tafamidis, characterized by a powder X-ray diffraction pattern, as illustrated by Figure 24.
  • the present invention provides a crystalline Form-T3 of Tafamidis, characterized by a PXRD pattern comprising the peaks at about 14.43, 21.59 and 22.95 0 ⁇ 0.2° 2Q.
  • the crystalline Form-T3 is characterized by one or more additional peaks at about 8.14, 17.33 and 22.33° ⁇ 0.2° 2Q.
  • the present application provides crystalline Form- T3 of Tafamidis, characterized by a powder X-ray diffraction pattern, as illustrated by Figures 25.
  • the present invention provides a crystalline Form-T4 of Tafamidis, characterized by a PXRD pattern comprising the peaks at about 8.17, 21.09, 24.75° ⁇ 0.2° 2Q.
  • the crystalline Form-T4 is characterized by one or more additional peaks at about 15.14, 22.76 and 27.88° ⁇ 0.2° 2Q.
  • the present application provides crystalline Form- T4 of Tafamidis, characterized by a powder X-ray diffraction pattern, as illustrated by Figures 26.
  • the present invention provides a process for the preparation of crystalline Form-Tl of Tafamidis, comprising the step of combining Tafamidis with 2-methoxyethanol.
  • the present application provides a process for the preparation of crystalline Form-T2 of Tafamidis, comprising the step of combining Tafamidis with N-methyl-2-pyrrolidone.
  • the present application provides a process for the preparation of crystalline Form-T3 of Tafamidis, comprising the step of combining Tafamidis with dimethylacetamide.
  • the present application provides a process for the preparation of crystalline Form-T4 of Tafamidis, comprising the step of combining Tafamidis with dimethylsulfoxide.
  • Tafamidis used in the preparation of crystalline form- Tl, form-T2, form-T3 or form-T4 may be obtained by any methods known in the art or a reaction mixture comprising Tafamidis may be used directly.
  • the crystalline forms of Tafamidis of the present application are stable under thermal, humid and stress conditions. Further, the crystalline forms of present application exhibits superior solubility in solvents such as water, as compared to reported crystalline forms of Tafamidis.
  • the present application provides a crystalline Tafamidis, selected from Form-Tl, Form-T2, Form-T3 and Form-T4, or the pharmaceutical compositions thereof, comprising Tafamidis with a chemical purity of atleast 99% by HPLC or atleast 99.5% by HPLC or atleast 99.9% by HPLC.
  • the suitable organic solvent at any stage of the process of the present invention may be selected from the group consisting of alcohols, such as methanol, ethanol, 2-propanol, n-butanol, isoamyl alcohol and ethylene glycol; ethers, such as diisopropyl ether, methyl tert -butyl ether, diethyl ether, 1,4- dioxane, tetrahydrofuran (THF), methyl THF, and diglyme; esters, such as ethyl acetate, isopropyl acetate, and t-butyl acetate; ketones, such as acetone and methyl isobutyl ketone; halogenated hydrocarbons, such as dichloromethane, dichloroethane, chloroform, and the like; nitriles, such as acetonitrile; polar aprotic solvents, such as N,N-dimethylformamide, N,N-di
  • Suitable temperatures for the reaction at any stage of the process of the present invention may be less than about 150°C, less than about 100°C, less than about 80°C, less than about 60°C, or any other suitable temperatures.
  • Suitable times for the hydrogenation step at any stage of the process of the present invention may be from about 30 minutes to about 10 hours, or longer.
  • removal of solvent at any stage of the process of the present invention may be carried out by methods known in the art or any procedure disclosed in the present application.
  • removal of solvent may include, but not limited to: solvent evaporation or sublimation under atmospheric pressure or reduced pressure / vacuum such as a rotational distillation using Biichi® Rotavapor®, spray drying, freeze drying (Lyophilization), agitated thin film drying and the like.
  • the compounds at any stage of the process of the present invention may be isolated using conventional techniques known in the art.
  • useful techniques include but are not limited to, decantation, centrifugation, gravity filtration, suction filtration, concentrating, cooling, stirring, shaking, combining with an anti-solvent, adding seed crystals, evaporation, flash evaporation, simple evaporation, rotational drying, spray drying, thin-film drying, freeze-drying, or the like.
  • the isolation may be optionally carried out at atmospheric pressure or under reduced pressure.
  • the solid that is obtained may carry a small proportion of occluded mother liquor containing a higher percentage of impurities and, if desired, the solid may be washed with a solvent to wash out the mother liquor.
  • the compounds at any stage of the process of the present invention may be recovered from a suspension/solution using any of techniques such as decantation, filtration by gravity or by suction, centrifugation, slow evaporation, or the like, or any other suitable techniques.
  • the reaction can be efficiently completed at room temperature or ambient temperature or if required reaction mass can be heated to elevated temperatures or up to about the reflux temperatures, and maintained for about 10 minutes to about 5 hours or longer.
  • the resulting solid may be optionally further dried. Drying may be suitably carried out using equipment such as a tray dryer, vacuum oven, air oven, fluidized bed dryer, spin flash dryer, flash dryer, or the like, at atmospheric pressure or under reduced pressure. Drying may be carried out at temperatures less than about 100°C, less than about 60°C, less than about 40°C, or any other suitable temperatures, at atmospheric pressure or under reduced pressure, and in the presence or absence of an inert atmosphere such as nitrogen, argon, neon, or helium. The drying may be carried out for any desired time periods to achieve a desired purity of the product, such as, for example, about 1 to about 15 hours, or longer.
  • Tafamidis or its meglumine salt of present invention has average particle size of particles between 1 to 100 pm, less than 90 pm, less than 80 pm, less than 60 pm, less than 50 pm, less than 40 pm, less than 30 pm, less than 20 pm, less than 10 pm, less than 5 pm or any other suitable particle sizes.
  • Tafamidis or its meglumine salt of present invention may have particle size distribution: D10 of particles smaller than 20 pm, smaller than 15 pm, smaller than 10 pm, or smaller than 5 pm; D50 of particles smaller than 100 pm, smaller than 90 pm, smaller than 80 pm, smaller than 70 pm, smaller than 60 pm, smaller than 50 pm, smaller than 40 pm, smaller than 30 pm, smaller than 20 pm, smaller than 10 pm; D90 of particles smaller than 200 pm, smaller than 175 pm, smaller than 150 pm, smaller than 140 pm, smaller than 130 pm, smaller than 120 pm, smaller than 110 pm, smaller than 100 pm, smaller than 90 pm, smaller than 80 pm, smaller than 70 pm, smaller than 60 pm, smaller than 50 pm, smaller than 40 pm, smaller than 30 pm, smaller than 20 pm, smaller than 10 pm.
  • Particle size distributions of Tafamidis or its meglumine salt particles may be measured using any techniques known in the art.
  • particle size distributions of Tafamidis or its meglumine salt particles may be measured using microscopy or light scattering equipment, such as, for example, a Malvern Master Size 2000 from Malvern Instruments Limited, Malvern, Worcestershire, United Kingdom.
  • DIO in the context of the present invention is 10% of the particles by volume are smaller than the DIO value and 90% particles by volume are larger than the DIO value.
  • D50 in the context of the present invention is 50% of the particles by volume are smaller than the D50 value and 50% particles by volume are larger than the D50 value.
  • D90 in the context of the present invention is 90% of the particles by volume are smaller than the D90 value and 10% particles by volume are larger than the D90 value.
  • Tafamidis or its meglumine salt of present invention can be micronized or milled using conventional techniques to get the desired particle size to achieve desired solubility profile to suit to pharmaceutical composition requirements.
  • Techniques that may be used for particle size reduction include, but not limited to ball milling, roller milling and hammer milling. Milling or micronization may be performed before drying, or after the completion of drying of the product.
  • the compounds of this application are best characterized by the X-ray powder diffraction pattern determined in accordance with procedures that are known in the art.
  • PXRD data reported herein was obtained using CuKa radiation, having the wavelength 1.5406 A and were obtained using a PANalytical X’Pert PRO instruments.
  • PANalytical X’Pert PRO instruments For a discussion of these techniques see J. Haleblain, J. Pharm. Sci. 1975 64:1269-1288, and J. Haleblain and W. McCrone, J. Pharm. Sci. 1969 58:911-929.
  • TG-DTA Thermogravimetry-differential thermal analysis
  • the solid was combined with water (1.5 litres) at 28 °C and stirred for 30 minutes. The solid was filtered and washed with water (500 mL). The solid was again combined with water (1.5 litres) at 28 °C and stirred for 30 minutes. The solid was filtered and washed with water (500 mL). The wet solid was dried in hot air oven at 70 °C for 16 hours to obtain 90 g of the title compound as a solid with HPLC purity of 97.1%
  • the mixture was cooled to 26 °C and added to water (4.5 litres).
  • the reaction mixture was stirred at 26 °C for 16 hours.
  • the solids were allowed to settle down and the supernatant liquid was separated out.
  • Water (4.5 litres) was added to the solids and the suspension was stirred at 26 °C for 5 hours and filtered.
  • the solid was dried in a hot air oven at 80 °C.
  • the dried compound was stirred with 30% ethyl acetate in hexane (0.75 litres) for 2 hours at 26 °C and filtered.
  • the solid was washed with 30% ethyl acetate in hexane (2 x 0.375 litres) and dried under vacuum for 2 hours to obtain a pale brown colored solid with HPLC purity of 93.38%.
  • the dry solid (129 g) was combined with tetrahydrofuran (3.87 litres) and the reaction mixture was heated to 60 °C.
  • Activated carbon (12.9 g) was added to the mixture at 60 °C and the suspension was stirred for 1 hour at the same temperature.
  • the mixture was then filtered through celite bed. The filtrate was cooled to 25 °C and added slowly to water (5.16 litres), and the suspension was stirred for 2 hours at 25 °C.
  • Example-3 Preparation of meglumine salt of Tafamidis A mixture of Tafamidis (80 g) in isopropyl alcohol (1.6 litres) was heated to 74 °C and water (280 ml) was added.
  • Example-4 Purification of Tafamidis A mixture of Tafamidis (84 g, HPLC purity: 98.0%) in isopropyl alcohol (1.7 litres) was heated to 74 °C and water (300 ml) was added. A solution of N- Methyl-D-glucamine (Meglumine) (53.2 g) in water (170 mL) was added to the above mixture at 72 °C and the resultant mixture was stirred for 2 hours at the same temperature. The mixture was filtered through celite bed and the filtrate was concentrated to nearly half its volume (1000 mL) at 50 °C under reduced pressure. The mixture was stirred at 26 °C for 18 hours and the solid was filtered.
  • Meglumine N- Methyl-D-glucamine
  • the solid was washed with isopropyl alcohol (84 mL) and dried in a hot air oven at 70 °C for 4 hours to obtain 115 g of Tafamidis meglumine salt as an off-white solid.
  • the meglumine salt was combined with water (1150 mL), the pH of the resulting mixture was adjusted to 4 with 2 N HC1 (90 mL) at 26 °C and the resultant suspension was stirred at the same temperature for 2 hours.
  • the solid was filtered and washed with water (575 mL). The wet solid was dried in a hot air oven at 80 °C for 16 hours to obtain 70.0 g of title compound as an off-white solid with HPLC purity of 99.22%.
  • Tafamidis (15 g, HPLC purity: 96.8%) was dissolved in 2 N sodium hydroxide solution (300 mL) at 25 °C and the mixture was washed with ethyl acetate (2 x 150 mL). The aqueous layer was separated, cooled to 0 °C and the pH was adjusted to 2 by addition of 1 N hydrochloric acid. The resulting suspension was stirred for 2 hours at 25 °C. The solid was filtered and washed with water (2 x 300 mL) and hexane (150 mL). The solid was dried under vacuum at 30 °C for 4 hours to obtain the of title compound as an off-white solid with HPLC purity of 98.06%.
  • Tafamidis (2 g, HPLC purity 98.0%) was dissolved in tetrahydrofuran (100 mL) at 26 °C and benzylamine (0.65 mL) was added. The reaction mixture was stirred for 17 hours at 26 °C and the solid was filtered. The wet solid was washed with tetrahydrofuran (6 mL) and dried in a hot air oven at 80 °C for 6 hours to obtain 1.1 g of the benzylamine salt of Tafamidis as an off-white crystalline solid with 99.8% purity by HPLC. The benzylamine salt (0.85 g) obtained above was combined with water (8.5 mL) at 26 °C.
  • the solid was filtered and washed with 25% acetone in water (2.34 mL).
  • the wet solid was dried in hot air oven at 80 °C for 18 hours to obtain 0.35 g of the title compound as an off-white solid with HPLC purity of 99.9%.
  • Tafamidis (2 g, HPLC purity 98.0%) was dissolved in dimethyl suphoxide (80 mL) at 26 °C and benzylamine (0.65 mL) was added. The reaction mixture was stirred for 17 hours at 26 °C and the solid was filtered. The wet solid was washed with dimethyl suphoxide (10 mL) and dried in hot air oven at 80 °C for 6 hours to obtain 2.2 g of the benzylamine salt of Tafamidis as off-white crystalline solid with 99.7% purity by HPLC. The benzylamine salt (2 g) obtained above was combined with water (20 mL) at 26 °C.
  • the solid was filtered and washed with 25% acetone in water (8.45 mL).
  • the wet solid was dried in a hot air oven at 80 °C for 18 hours to obtain 1.16 g of the title compound as an off-white solid with traces of benzylamine present.
  • the dried solid was combined with a mixture of 25% acetone in water (11.6 mL) at 26 °C. 2 N hydrochloric acid (2.3 mL) was added to the reaction mixture and the suspension obtained was stirred for 2 hours at 26 °C the same temperature.
  • the solid was filtered and washed with 25% acetone in water (5.8 mL).
  • the wet solid was dried in a hot air oven at 80 °C for 18 hours to obtain 1.06 g of the title compound as an off-white solid with HPLC purity of 99.7%.
  • Tafamidis (1.5 g, HPLC purity 98.0%) was dissolved in dimethyl suphoxide (60 mL) at 26 °C and dicyclohexylamine (0.93 mL) was added. The reaction mixture was stirred for 16 hours at 26 °C and the solid was filtered. The wet solid was washed with dimethyl suphoxide (4.5 mL) and dried in a hot air oven at 80 °C for 6 hours to obtain 2.0 g of the dicyclohexylamine salt of Tafamidis as an off- white crystalline solid with 99.5% purity by HPLC. The salt (1.74 g) obtained above was combined with water (17.4 mL) at 26 °C.
  • Tafamidis (1.5 g, HPLC purity 98.0%) was dissolved in tetrahydrofuran (75 mL) at 26 °C and dicyclohexylamine (0.93 mL) was added. The reaction mixture was stirred for 16 hours at 26 °C and the solid was filtered. The wet solid was washed with tetrahydrofuran (4.5 mL) and dried in hot air oven at 80 °C for 6 hours to obtain 1.86 g of the dicyclohexylamine salt of Tafamidis as off-white crystalline solid with 99.5% purity by HPLC. The dicyclohexylamine salt (1.74 g) obtained above was combined with water (17.4 mL) at 26 °C.
  • the solid was filtered and washed with 25% acetone in water (4.25 mL).
  • the wet solid was dried in a hot air oven at 80 °C for 18 hours to obtain 0.49 g of the title compound as off-white solid with HPLC purity of 99.5 %.
  • Tafamidis (100 mg, HPLC purity 98.0%) was dissolved in tetrahydrofuran (5 mL) at 26 °C and diethanolamine (0.03 mL) was added. The reaction mixture was stirred for 16 hours at 26 °C and the solid was filtered. The wet solid was washed with tetrahydrofuran (1 mL) and dried under vacuum at 46 °C for 45 min to obtain 120 mg of the diethanolamine salt of Tafamidis as off-white crystalline solid with 99.6% purity by HPLC. The diethanolamine salt (60 mg) obtained above was combined with water (1.8 mL) at 26 °C.
  • Example-11 Preparation of amorphous solid dispersion of Tafamidis with povidone.
  • Example-12 Preparation of amorphous solid dispersion of Tafamidis with copovidone.
  • Example-13 Preparation of solid dispersion of Tafamidis with HPMC.
  • Example-14 Preparation of solid dispersion of Tafamidis with HPC.
  • Example-15 Preparation of amorphous Tafamidis meglumine.
  • Tafamidis meglumine 250 mg was dissolved in water (25 mL) at 27 °C and the solution was frozen at -78 °C. The frozen solution was lyophilized for 16 hours under reduced pressure to obtain 225 mg of the title compound as a solid. The solid (100 mg) was combined with Syloid 244 FP (100 mg) and ground in a mortar-pestle for 30 minutes to obtain the premix of the title compound.
  • PXRD Amorphous.
  • Example-16 Preparation of amorphous solid dispersion of Tafamidis meglumine with copovidone.
  • Tafamidis meglumine (250 mg) and copovidone (250 mg) were dissolved in water (40 mL) at 27 °C and the solution was frozen at -78 °C. The frozen solution was lyophilized for 16 hours under reduced pressure to obtain 460 mg of the title compound as a solid dispersion.
  • the solid dispersion (100 mg) was combined with Syloid 244 FP (100 mg) and ground in a mortar-pestle for 30 minutes to obtain the premix of the title compound.
  • PXRD Amorphous.
  • Example-17 Preparation of amorphous solid dispersion of Tafamidis meglumine with povidone.
  • Tafamidis meglumine (250 mg) and povidone K-30 (250 mg) were dissolved in water (40 mL) at 27 °C and the solution was frozen at -78 °C. The frozen solution was lyophilized for 16 hours under reduced pressure to obtain 475 mg of the title compound as a solid dispersion.
  • the solid dispersion (100 mg) was combined with Syloid 244 FP (100 mg) and ground in a mortar-pestle for 30 minutes to obtain the premix of the title compound.
  • PXRD Amorphous.
  • Example-18 Preparation of amorphous solid dispersion of Tafamidis meglumine with HPMC.
  • Tafamidis meglumine (250 mg) and HPMC (250 mg) were dissolved in water (40 mL) at 27 °C and the solution was frozen at -78 °C. The frozen solution was lyophilized for 16 hours under reduced pressure to obtain 450 mg of the title compound as a solid dispersion.
  • the solid dispersion (100 mg) was combined with Syloid 244 FP (100 mg) and ground in a mortar-pestle for 60 minutes to obtain the premix of the title compound.
  • PXRD Amorphous.
  • Example-19 Preparation of amorphous solid dispersion of Tafamidis meglumine with Soluplus.
  • Tafamidis meglumine (250 mg) and Soluplus (250 mg) were dissolved in water (25 mL) at 27 °C and the solution was frozen at -78 °C. The frozen solution was lyophilized for 16 hours under reduced pressure to obtain 440 mg of the title compound as a solid dispersion.
  • the solid dispersion (100 mg) was combined with Syloid 244 FP (100 mg) and ground in a mortar-pestle for 30 minutes to obtain the premix of the title compound.
  • PXRD Amorphous.
  • Example-20 Preparation of crystalline Form-Tl of Tafamidis.
  • Example-21 Preparation of crystalline Form-T2 of Tafamidis.
  • Example-22 Preparation of crystalline Form-T3 of Tafamidis.
  • Example-23 Preparation of crystalline Form-T4 of Tafamidis.
  • Example-24 Preparation of crystalline Form-T4 of Tafamidis.
  • Example-25 Preparation of meglumine salt of Tafamidis.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des procédés améliorés pour la préparation de tafamidis et d'un sel de celui-ci. La présente invention concerne également un procédé monotope pour la préparation de tafamidis et sa purification. La présente invention concerne des dispersions solides amorphes de tafamidis et de son sel de méglumine, ainsi que leurs procédés. La présente invention concerne également de nouvelles formes cristallines de tafamidis et leurs procédés.
PCT/IN2021/050078 2020-01-27 2021-01-25 Procédés améliorés pour la préparation de tafamidis et de son sel de méglumine WO2021152623A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN202041003544 2020-01-27
IN202041003544 2020-01-27
IN202041003545 2020-01-27
IN202041003545 2020-01-27
IN202041025759 2020-06-18
IN202041025759 2020-06-18

Publications (1)

Publication Number Publication Date
WO2021152623A1 true WO2021152623A1 (fr) 2021-08-05

Family

ID=77078624

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2021/050078 WO2021152623A1 (fr) 2020-01-27 2021-01-25 Procédés améliorés pour la préparation de tafamidis et de son sel de méglumine

Country Status (1)

Country Link
WO (1) WO2021152623A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3191461B1 (fr) 2014-09-08 2021-11-03 Pfizer Inc. Formes cristallines solides du 6-carboxy-2-(3,5-dichlorophényl)-benzoxazole
CN113735792A (zh) * 2021-09-22 2021-12-03 上海新礼泰药业有限公司 氯苯唑酸葡胺及其中间体的制备方法
WO2023091534A1 (fr) * 2021-11-17 2023-05-25 Teva Pharmaceuticals International Gmbh Forme à l'état solide de tafamidis
WO2023203503A1 (fr) * 2022-04-20 2023-10-26 Glenmark Life Sciences Limited Procédé de préparation de tafamidis
US11878081B1 (en) 2022-12-23 2024-01-23 Tap Pharmaceuticals Ag Pharmaceutical formulations of tafamidis
WO2024019180A1 (fr) * 2022-07-22 2024-01-25 白鳥製薬株式会社 Procédé de production de tafamidis ou d'un sel de celui-ci
US11980685B1 (en) 2022-12-23 2024-05-14 Tap Pharmaceuticals, Ag Liquid pharmaceutical formulations of tafamidis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214695B2 (en) * 2002-12-19 2007-05-08 The Scripps Research Institute Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
WO2016038500A1 (fr) * 2014-09-08 2016-03-17 Pfizer Inc. Formes cristallines solides du 6-carboxy-2-(3,5-dichlorophényl)-benzoxazole
WO2019175263A1 (fr) * 2018-03-13 2019-09-19 Azad Pharma Ag Nouveaux polymorphes et nouvelle voie de synthèse de tafamidis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214695B2 (en) * 2002-12-19 2007-05-08 The Scripps Research Institute Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
WO2016038500A1 (fr) * 2014-09-08 2016-03-17 Pfizer Inc. Formes cristallines solides du 6-carboxy-2-(3,5-dichlorophényl)-benzoxazole
WO2019175263A1 (fr) * 2018-03-13 2019-09-19 Azad Pharma Ag Nouveaux polymorphes et nouvelle voie de synthèse de tafamidis

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3191461B1 (fr) 2014-09-08 2021-11-03 Pfizer Inc. Formes cristallines solides du 6-carboxy-2-(3,5-dichlorophényl)-benzoxazole
CN113735792A (zh) * 2021-09-22 2021-12-03 上海新礼泰药业有限公司 氯苯唑酸葡胺及其中间体的制备方法
WO2023091534A1 (fr) * 2021-11-17 2023-05-25 Teva Pharmaceuticals International Gmbh Forme à l'état solide de tafamidis
WO2023203503A1 (fr) * 2022-04-20 2023-10-26 Glenmark Life Sciences Limited Procédé de préparation de tafamidis
WO2024019180A1 (fr) * 2022-07-22 2024-01-25 白鳥製薬株式会社 Procédé de production de tafamidis ou d'un sel de celui-ci
US11878081B1 (en) 2022-12-23 2024-01-23 Tap Pharmaceuticals Ag Pharmaceutical formulations of tafamidis
US11980685B1 (en) 2022-12-23 2024-05-14 Tap Pharmaceuticals, Ag Liquid pharmaceutical formulations of tafamidis

Similar Documents

Publication Publication Date Title
WO2021152623A1 (fr) Procédés améliorés pour la préparation de tafamidis et de son sel de méglumine
US20160194301A1 (en) Preparation of lenalidomide
US8258327B2 (en) Crystalline minocycline base and processes for its preparation
US20220402874A1 (en) Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
SK862003A3 (en) Carvedilol
JP2020513023A (ja) ルマテペロンｐ−トシラートの非晶質形態および固体分散体
WO2019135254A1 (fr) Polymorphes d'apalutamide et leur préparation
US20190300483A1 (en) POLYMORPHS OF BETRlXABAN & ITS MALEATE SALT
WO2020208592A1 (fr) Procédé de préparation d'erdafitinib, sa purification et dispersion solide amorphe
WO2022054096A1 (fr) Formes solides de composés de pyridone polycycliques substitués et leurs promédicaments et leur procédé de préparation
WO2019049174A1 (fr) Formes à l'état solide de chlorhydrate de 5-chloro-6-[(2-iminopyrrolidin-1-yl)méthyl]pyrimidine-2,4-(1h,3h)-dione et procédés de préparation associés
US20240082248A1 (en) Process for preparation of mavacamten and solid state forms thereof
WO2021074842A1 (fr) Procédé amélioré pour la préparation de fumarate de diroximel et formes solides de celui-ci
WO2018134843A1 (fr) Formes polymorphes de (e)-n-{4-[3-chloro-4-((pyridin-2-yl-méthoxy)-anilino]-3-cyano-7-éthoxyquinolin-6-yl)-4-(diméthylamino)-but-2-énamide, son sel de maléate et un procédé de préparation correspondant
US20220259209A1 (en) Process for the preparation of abrocitinib
WO2000029383A1 (fr) Formes cristallines du 3-(2,4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3h-benzimidazole-5-carboxamide
US20220220080A1 (en) Process for the preparation of high purity levosimendan
US20080188658A1 (en) Novel synthesis of gatifloxacin
WO2017216761A1 (fr) Formes solides d'entinostat
WO2021117062A1 (fr) Procédé de préparation de 4-[7-(6-cyano-5-trifluorométhylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-n-méthylbenzamide et de ses polymorphes
WO2023152773A1 (fr) Formes solides de sels de momélotinib et procédés améliorés pour la préparation de momélotinib
WO2024084426A1 (fr) Formes solides de 3,3'-dioxo-[δ2,2'-biindoline]-5,5'-disulfonate disodique et leur procédé de préparation
JP2012500268A (ja) ７−クロロ−Ｎ，Ｎ，５−トリメチル−４−オキソ−３−フェニル−３，５−ジヒドロ−４Ｈ−ピリダジノ［４，５−ｂ］インドール−１−アセトアミドの多形体を製造するための方法
WO2022234602A1 (fr) Procédé de préparation de formes solides de 4-{8-amino-3-[(2s)-1-(but-2-ynoyl) pyrrolidin-2-yl] imidazo[1,5-a] pyrazin-1-yl)}-n- (pyridine-2-yl) benzamide
WO2022208552A1 (fr) Formes cristallines du [1,1'-biphényl]-3-carboxamide, n-[(1,2-dihydro-4,6-diméthyl-2-oxo-3-pyridinyl)méthyl]-5-[éthyl(tétrahydro-2h-pyran-4-yl)amino]-4-méthyl-4'-(4-morpholinylméthyl)-, bromhydrate (1:1) et son procédé de préparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21747238

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21747238

Country of ref document: EP

Kind code of ref document: A1